Akebia Completes $22M Series B Financing

Akebia Therapeutics, Inc., a pharmaceutical discovery and development company, is pocketing $22 million in venture funds assigned to its second round. The money is being earmarked for work on new treatments for anemia and vascular disorders.

"This is an important financing event for Akebia because it enables us to complete two phase 2b studies for our anemia drug, AKB-6548 and will position the program for pivotal studies," said Joseph Gardner, Ph.D., the CEO of Akebia. "This financing round also enables us to advance AKB-9778, our novel Tie-2 activator for diabetic macular edema and vascular leak,